Dissolution test for oral suspension
an overview about use and importance
DOI:
https://doi.org/10.1590/s2175-97902022e19423Palavras-chave:
Dissolution, Suspension, Therapeutic equivalence, RegulatoryResumo
This work aims to ascertain the comprehensiveness of dissolution tests for oral suspensions registered in Brazil and the USA. After consulting literature since 1994, a paucity of information about dissolution methods for suspensions was detected. It makes it difficult to establish the most appropriate test parameters. In January, 2019, there were 46 drugs registered in Anvisa (Brazil) as oral suspension, being 47 reference, 173 generic and 114 interchangeable similar (IS) medicines; while in the USA, 90 drugs were registered as oral suspension by FDA, 235 Abreviatted New Drug Application and 111 New Drug Application medicines. Out of 46 and 90, only six and 15 drugs as oral suspension had a pharmacopeial dissolution test, corresponding to 70 (20.9%) and 82 (23.7%) products in Brazil and the USA, respectively. Dissolution studies were found for 17 drugs as oral suspension in the non-compendial literature. Dissolution test conditions were established to few marketable oral suspension drugs, most of which are BCS class II or IV. Thus, investing in dissolution studies could subsidize the registration of these products by regulators, especially for generic and IS drugs, by comparing dissolution profiles, and predicting their in vivo behavior to avoid exposure of healthy individuals to clinical research.
Downloads
Referências
Aiache J, Aoyagi N, Blume H, Dressman J, Friedel H, Grady L, et al. FIP guidelines for dissolution testing of solid oral products. Dissolut Technol. 1997;4(4):5-14.
Allen L, Popovich N, Ansel H. Pharmaceutical dosage forms and drug delivery systems. 9th Edition. Philadelphia: Lippincott Williams & Wilkins; 2012.
Amidon G, Lennernäs H, Shah V, Crison J. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413-20.
Agência Nacional de Vigilância Sanitária. Anvisa. Farmacopeia Brasileira. 5ª ed. Brasília: Anvisa; 2010b.
Agência Nacional de Vigilância Sanitária. Anvisa. Farmacopeia Brasileira . 5ª ed. 1º Supl. Brasília: Anvisa ; 2016b.
Agência Nacional de Vigilância Sanitária. Anvisa. Farmacopeia Brasileira . 5ª ed. 2º Supl. Brasília: Anvisa ;2017.
Agência Nacional de Vigilância Sanitária. Anvisa. Farmacopeia Brasileira . v. I, 6ª ed. Brasília: Anvisa ;2019a.
Agência Nacional de Vigilância Sanitária. Anvisa. Farmacopeia Brasileira . v. II, 6ª ed. Brasília: Anvisa ;2019b.
Agência Nacional de Vigilância Sanitária. Anvisa. Lista A de medicamentos de referência. Anvisa; 2019c. 52p. [Citad 2019 Jan 2]. Available from: Available from: http://portal.anvisa.gov.br/registros-e-autorizacoes/medicamentos/produtos/medicamentos-de-referencia/lista
Agência Nacional de Vigilância Sanitária. Anvisa. Lista B de medicamentos de referência. Anvisa; 2019d. 18p. [Citad 2019 Jan 2]. Available from: Available from: http://portal.anvisa.gov.br/registros-e-autorizacoes/medicamentos/produtos/medicamentos-de-referencia/lista
Agência Nacional de Vigilância Sanitária. Anvisa. Lista de medicamentos genéricos registrados na Anvisa classificados por ordem alfabética. Anvisa; 2019e. 88p. [Citad 2019 Jan 2]. Available from: Available from: http://portal.anvisa.gov.br/medicamentos-genericos-registrados
» http://portal.anvisa.gov.br/medicamentos-genericos-registrados
Agência Nacional de Vigilância Sanitária. Anvisa. Lista de medicamentos similares e seus respectivos medicamentos de referência conforme RDC 58/2014. Anvisa; 2019f. 226p. [Citad 2019 Jan 2]. Available from: Available from: http://portal.anvisa.gov.br/medicamentos-similares
» http://portal.anvisa.gov.br/medicamentos-similares
Agência Nacional de Vigilância Sanitária. Anvisa. Resolução de Diretoria Colegiada no. 31, de 11 de agosto de 2010. Estudos de equivalência farmacêutica e de perfil de dissolução comparativo. Diário Oficial da União 12 ago 2010a; Seção 1. n. 154: 36-8p.
Agência Nacional de Vigilância Sanitária. Anvisa. Resolução de Diretoria Colegiada no. 37, de 6 de julho de 2009. Trata da admissibilidade das farmacopeias estrangeiras. Diário Oficial da União 8 jul 2009; Seção 1. n. 128.
Agência Nacional de Vigilância Sanitária. Anvisa. Resolução de Diretoria Colegiada no. 37, de 3 de agosto de 2011. Dispõe sobre o Guia para isenção e substituição de estudos de biodisponibilidade relativa/bioequivalência e dá outras providências. Diário Oficial da União 05 ago 2011; Seção 1. n. 150, p.117.
Agência Nacional de Vigilância Sanitária. Anvisa. Resolução de Diretoria Colegiada no. 58, de 10 de outubro de 2014. Dispõe sobre as medidas a serem adotadas junto à Anvisa pelos titulares de registro de medicamentos para a intercambialidade de medicamentos similares com o medicamento de referência. Diário Oficial da União 13 out 2014; Seção 1. n 197: 659-60p.
Agência Nacional de Vigilância Sanitária. Anvisa. Resolução de Diretoria Colegiada no. 73, de 7 de abril de 2016. Dispõe sobre mudanças pós-registro, cancelamento de registro de medicamentos com princípios ativos sintéticos e semissintéticos e dá outras providências. Diário Oficial da União 08 abr 2016a; Seção 1. n. 67: 32-41p.
British Pharmacopoeia. BP. 2014. London: Stationery Office (Great Britain); 2013. 5860p.
British Pharmacopoeia. BP. 2018. London: Stationery Office (Great Britain) ; 2017.
Brown C, Friedel H, Barker A, Buhse L, Keitel S, Cecil T, et al. FIP/AAPS joint workshop report: dissolution/in vitro release testing of novel/special dosage forms. Indian J Pharm Sci. 2011;73(3):338-53.
da Fonseca LB, Labastie M, Sousa VP, Volpato NM. Development and validation of a discriminative dissolution test for nimesulide suspensions. AAPS PharmSciTech. 2009;10(4):1145-52.
Dressman J, Amidon G, Reppas C, Shah V. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res. 1998;15(1):11-22.
European Medicines Evaluation Agency. EMEA. Committee for medicinal products for human use (CHMP). Guidance on the Investigation of Bioequivalence. London: Jan 20, 2010.
Farmacopéia Brasileira. Comissão Permanente de Revisão da Farmacopeia Brasileira . 3ª ed. São Paulo: Andrei; 1977. 1213p.
Farmacopéia Brasileira. Comissão Permanente de Revisão da Farmacopeia Brasileira . 4ª ed. São Paulo: Atheneu; 2000. 282p.
Food and Drug Administration. FDA. Dissolution Methods. 2019b. [Citad 2019 Jan 8] Available from: Available from: http://www.accessdata.fda.gov/scripts/cder/dissolution/dsp_getallData.cfm
» http://www.accessdata.fda.gov/scripts/cder/dissolution/dsp_getallData.cfm
Food and Drug Administration. FDA. Guidance for Industry: bioavailability and bioequivalence studies submitted in NDAs or INDs - General considerations. U.S. Department of Health and Human Services. USA: FDA; 2014. 26p.
Food and Drug Administration. FDA. FDA. Guidance for industry: dissolution testing of immediate release solid oral dosage forms. U.S. Department of health and human services, Food and Drug Administration, Center for Drug Evaluated and Research (CDER). Rockville: FDA, 1997. p.1-17
Food and Drug Administration. FDA. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. U.S. Department of Health and Human Services. USA: FDA ; 2017.
Food and Drug Administration. FDA. Orange book: approved drug products with therapeutic equivalence evaluations. 2019a. [Citad 2019 Jan 8] Available from: Available from: http://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm
» http://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm
Friedel HD, Brown CK, Barker AR, Buhse LF, Keitel S, Kraemer J, et al. FIP guidelines for dissolution testing of solid oral products. J Pharm Sci. 2018;107(12):2995-3002.
International Pharmaceutics Federation. FIP. Biowaiver monographs. 2018 [Citad 2019 Mar 03] Available from: Available from: https://www.fip.org/files/fip/BPS/BCS/FIP_biowaiver_progress_table_181203.pdf
» https://www.fip.org/files/fip/BPS/BCS/FIP_biowaiver_progress_table_181203.pdf
Klein S. The Use of biorrelevant dissolution media to forecast the in vivo performance of a drug. AAPS Journal. 2010;12(3):397-406.
Lajoinie A, Henin E, Kassai B. Oral formulation of choice for children. Arch Pediatr. 2015;22(8):877-85.
Limberg J, Potthast H. Regulatory status on the role of in vitro dissolution testing in quality control and biopharmaceutics in Europe. Biopharm Drug Dispos. 2013;34(5):247-53.
Mishra V, Gupta U, Jain N. Biowaiver: an alternative to in vivo pharmacokinetic bioequivalence studies. Pharmazie. 2010;65(3):155-61.
Pharmacopeial Forum. 44(5). General chapter <1711> Oral Solid Dosage Forms - Dissolution Testing (USP42-NF37 2S), 2019. Available from: https://uspnf.com/sites/default/files/usp_pdf/pf-44-5-toc-archive.pdf
» https://uspnf.com/sites/default/files/usp_pdf/pf-44-5-toc-archive.pdf
Phillips D, Pygall S, Cooper V, Mann J. Overcoming sink limitations in dissolution testing: a review of traditional methods and the potential utility of biphasic systems. J Pharm Pharmacol. 2012;64(11):1549-59.
Rohrs B. Dissolution method development for poorly soluble compounds. Dissolut Technol. 2001;8(3):1-5.
Shohin IE, Grebenkin DY, Malashenko EA, Stanishevskii YM, Ramenskaya GV. A brief review of the FDA dissolution methods database. Dissolut Technol. 2016;23(3):6-10.
Japanese Pharmacopoeia. JP. 17th ed, Tokyo: Yakuji Nippo Ltd., 2016. [Citad 2019 Fev 27]. Avaliable from: Avaliable from: https://www.pmda.go.jp/files/000225991.pdf
» https://www.pmda.go.jp/files/000225991.pdf
United States Pharmacopeia. USP. 22nd ed., Rockville: United States Pharmacopeial Convention; 1994.
United States Pharmacopeia. USP . 23rd ed., Rockville: United States Pharmacopeial Convention ; 1995.
United States Pharmacopeia. USP . 24th ed., Rockville: United States Pharmacopeial Convention ; 1996.
United States Pharmacopeia. USP . 29th ed., Rockville: United States Pharmacopeial Convention ; 2006.
United States Pharmacopeia. USP . 31st ed., Rockville: United States Pharmacopeial Convention ; 2008.
United States Pharmacopeia. USP . 32nd ed., Rockville: United States Pharmacopeial Convention ; 2009.
United States Pharmacopeia. USP . 34th ed., Rockville: United States Pharmacopeial Convention ; 2011.
United States Pharmacopeia. USP . 36th ed., Rockville: United States Pharmacopeial Convention ; 2013.
United States Pharmacopeia. USP . 41th ed., Rockville: United States Pharmacopeial Convention ; 2018.
Van Oudtshoorn JE, García-Arieta A, Santos GML, Crane C, Rodrigues C, Simon C, et al. A survey of the regulatory requirements for bcs-based biowaivers for solid oral dosage forms by participating regulators and organisations of the international generic drug regulators programme. J Pharm Pharm Sci. 2018;21(1):27-37.
World Health Organization. WHO. International Pharmacopoeia. 8th ed, Geneva: WHO Press, 2018. [Citad 2019 Fev 27]. Avaliable from: Avaliable from: http://apps.who.int/phint/en/p/docf
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
Como Citar
Dados de financiamento
-
Fundação de Amparo à Pesquisa do Estado de Minas Gerais
Números do Financiamento 02247-14 -
Pró-Reitoria de Pesquisa e Pós-Graduação, Universidade Federal de Ouro Preto
Números do Financiamento 232/2015 -
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
-
Conselho Nacional de Desenvolvimento Científico e Tecnológico
